| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Allergy and Respiratory Disease Clinic, Department of Internal Medicine, University of Genoa, Genoa, Italy;
Unité 506 Institut National de la Santé et de la Recherche Médicale, Villejuif, France;
Anesthesiology Unit, Dipartimento Scienze Chirurgiche Specialistiche, Anestesiologia e Trapianti d’Organo, University of Genoa, Genoa, Italy; and
Cellular Immunotherapy, Istituto Scientifico (per lo studio e la cura dei) Tumori, Genoa, Italy
CD40/CD40 ligand interaction is an important pathway for B and T cell cooperation and function; functional CD40 molecules have recently been found on nonhematopoietic cells. We detected CD40 in vivo on normal human respiratory epithelial cells and showed that its expression is increased on inflamed airway epithelium. Subsequently, we analyzed its expression and function on primary cultures of human airway epithelial cells. Our data show that CD40 is up-regulated by IFN-
and IFN-
, its ligation increases the surface expression of CD54 and CD106 and it may stimulate the release of IL-6 and IL-8. The use of Janus kinase 3 (JAK3) and NF-
B inhibitors suggests that both basal and CD40-induced release of the two cytokines is JAK3-dependent. Using colocalization techniques, we revealed the existence of CD40/JAK3 and CD40/TNFR-associated factor 2 interplay. The extent of these interactions may be partial (2–40% of the cells) or massive (80–90% of the cells) in cultured cells. Stimulation via CD40 causes a significant increase in the number of cells expressing colocalization only in the cultures displaying low frequency of initial colocalization. Thus, airway epithelial cells, activated by CD40, may behave as effector cells of the inflammation process and should be considered priority targets for anti-inflammatory therapy. This work identifies CD40 and the correlated JAK3 signaling molecule as potential molecular targets to block the inflammatory functions of epithelial cells.
This article has been cited by other articles:
|
|
 |
|
  Y.-T. Tai, E. Soydan, W. Song, M. Fulciniti, K. Kim, F. Hong, X.-F. Li, P. Burger, M. J. Rumizen, S. Nahar, et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells Blood, April 30, 2009; 113(18): 4309 - 4318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Hsi, R. Steinle, B. Balasa, S. Szmania, A. Draksharapu, B. P. Shum, M. Huseni, D. Powers, A. Nanisetti, Y. Zhang, et al. CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma Clin. Cancer Res., May 1, 2008; 14(9): 2775 - 2784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Danese, F Scaldaferri, S Vetrano, T Stefanelli, C Graziani, A Repici, R Ricci, G Straface, A Sgambato, A Malesci, et al. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease Gut, September 1, 2007; 56(9): 1248 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Barbe-Tuana, D. Klein, H. Ichii, D. M. Berman, L. Coffey, N. S. Kenyon, C. Ricordi, and R. L. Pastori CD40-CD40 Ligand Interaction Activates Proinflammatory Pathways in Pancreatic Islets Diabetes, September 1, 2006; 55(9): 2437 - 2445. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
